Project Grant R21AI203024
Award Date 8/14/26
Completion Date 7/31/28
Dollars Obligated $182K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $687,661 on July 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop albumin-hitchhiking intranasal vaccines that enhance immune protection against infectious disease. The project addresses the gap between traditional parenteral vaccines, which elicit poor mucosal immunity, and the need for protection at mucosal portals of pathogen entry such as...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $2,946,564 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to engineer immunocompetent human tissues and define inflammatory state transitions. The project develops tools to study chronic inflammation in complex human tissues by assembling immunocompetent microtissues derived from pluripotent stem cell progenitors in brain, liver, and adipose...
- The National Institute of Allergy and Infectious Diseases awarded $407,326 to the Regents of the University of Minnesota on February 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize the development, homeostasis, and specificity of HELIOS+ CD8+ T cells and their role in immune regulation. Research activities will establish model systems intended to dissect how these memory-phenotype CD8+ T cells, which express the transcription factor HELIOS,...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $380,000 on September 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop bespoke micellar nanoparticles for in vivo delivery of digital base editor treatments for primary immunodeficiency disease. The recipient will synthesize a novel uniform library of amphiphilic polymers and optimize micellar nanoparticles for binary base editor (guide RNA and...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $423,500 on February 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will generate and validate a series of TAM receptor tyrosine kinase (Tyro3, Axl, and Merkt) mutant mice designed to disentangle specific effector functions—phagocytosis of dead cells and anti-inflammatory signaling—rather than produce complete knockouts. By substituting...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota $713,107 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, assistance type: Project Grant) to investigate molecular determinants and vulnerabilities of HIV-1 spread through cell-to-cell transmission. The research examines how HIV-1 replicates and transmits between host cells via two routes: free virus circulation and direct cell-to-cell...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Minnesota a Project Grant totaling $420,771 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period July 7, 2025 through June 30, 2027. This grant supports research focused on developing next-generation genetic therapies for Artemis-deficient Severe Combined Immunodeficiency (ART-SCID), a primary immune deficiency disorder caused...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the Regents of the University of Minnesota $231,000 on June 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of natural killer cells in clearing Plasmodium erythrocytic stage parasites in vivo. The research addresses blood-stage malaria infection mechanisms underlying antibody-mediated protection, which remains poorly defined despite antibodies conferring known...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Minnesota a $437,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 25, 2025, with completion targeted for May 31, 2027. This research initiative focuses on advancing gene therapy delivery for lung-specific diseases by evaluating adeno-associated virus (AAV) vector systems packaged within extracellular vesicles. The project...
- The National Institute of Allergy and Infectious Diseases awarded a cooperative agreement of $331,353 to the Regents of the University of Minnesota on September 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds a phase II/III platform trial investigating the efficacy and safety of immunomodulatory therapy for HIV-related cryptococcal meningitis. The research addresses the damage-response immune framework underlying the disease, moving beyond...